Description

Buy Hubio Cagrilintide 10mg US

Hubio Cagrilintide is a research-grade long-acting amylin analogue, structurally derived from the 37-amino acid neuroendocrine peptide hormone amylin, which is co-secreted with insulin from pancreatic β-cells.  Amylin plays a fundamental role in modulating glucose and satiety signals, regulating hunger, gastric motility, glucagon secretion, and energy metabolism through divergent amylin receptor (AMYR) subtypes. 

Cagrilintide acts as a nonselective agonist at both amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR).  The compound features a fatty acid (C20 diacid) modification via a γGlu linker, which extends its half-life through albumin binding, enabling once-weekly administration in research protocols.  A pair of helix-stabilizing mutations (N14E and V17R) were incorporated to counteract amyloid fibril formation and stabilise the N-terminal α-helix of the peptide. 

In vitro studies have confirmed cagrilintide’s potent activity at both receptor targets. Structural studies using cryogenic electron microscopy (cryo-EM) have revealed that cagrilintide exhibits an amylin-like binding mode, with distinct conformational dynamics at calcitonin-family receptors compared to other peptides. 

Mechanism of Action

Cagrilintide exerts its effects through dual receptor agonism at amylin receptors (AMYR1, AMYR2, AMYR3) and the calcitonin receptor (CTR), which are heterodimers of the class B1 G protein-coupled calcitonin receptor and receptor activity-modifying proteins (RAMPs).  The compound induces satiety through central pathways and regulates gastric motility, glucagon secretion, and energy homeostasis. 

Preclinical research in rodent models has demonstrated that cagrilintide reduces food intake and induces significant weight loss.  Investigations into kidney-specific metabolic pathways have shown that cagrilintide elevates intracellular cAMP levels in cortical tubules and induces phosphorylation of ion transporters in the thick ascending limb of the loop of Henle and the distal convoluted tubule, suggesting a potential role in diabetic kidney physiology research.  The compound’s effects on weight regulation are believed to be mediated primarily through AMYR activation, with evidence suggesting that co-activation of both CTR and AMYRs may confer greater efficacy than selective AMYR activation. 

Clinical Research Context

In a phase 3 trial (REDEFINE 1) involving 3,417 adults with obesity or overweight without diabetes, once-weekly cagrilintide 2.4 mg monotherapy provided clinically meaningful weight loss: 

*based on trial product estimand; **based on treatment policy estimand 

In combination with the GLP-1 receptor agonist semaglutide (CagriSema), phase 3 trials in adults with type 2 diabetes and obesity demonstrated a mean weight reduction of 13.7% compared to 3.4% with placebo.  The most common adverse events were gastrointestinal (nausea, vomiting, diarrhoea, constipation), predominantly mild-to-moderate in severity. Nausea led to permanent discontinuation in 1.0% of participants. 

The dedicated phase 3 RENEW programme investigating cagrilintide in obesity is ongoing. 

Product Features

• 10 mg Research Unit Size: Suitable for laboratory protocols

• ≥99% Purity (HPLC): Manufactured to rigorous standards 

• Lyophilized Format: Stable powder for reliable reconstitution

• 37-Amino Acid Peptide: With fatty acid modification for extended half-life 

Research Applications

This product is suitable for laboratory research and preclinical studies in the following areas:

• Amylin Receptor Pathway Research: Investigating signaling mechanisms and metabolic effects 

• Obesity and Metabolic Research: Evaluating effects on energy balance, appetite regulation, and lipid metabolism 

• Gastric Motility Studies: Research on gastrointestinal function and regulation 

• Glucagon Regulation: Investigating effects on glucagon secretion and glycemic control 

• Diabetic Kidney Research: Exploring renal metabolic pathways and potential therapeutic mechanisms 

• Combination Therapy Models: Studying synergistic effects with GLP-1 receptor agonists 

Recommended Use

This product is intended solely for laboratory research purposes. The lyophilized powder must be reconstituted using sterile technique.

Reconstitution Instructions

1. Briefly centrifuge the vial before opening to bring contents to the bottom

2. Reconstitute in sterile distilled water or appropriate aqueous buffer

3. Gently swirl until completely dissolved; do not vortex or shake vigorously

4. Apportion stock solutions into working aliquots for research protocols

Storage Instructions

• Lyophilized Powder: Store at -20°C, sealed, away from moisture and light, under nitrogen 

• In Solution: Store at -80°C; avoid repeated freeze-thaw cycles 

Research Use Disclaimer

This product is intended solely for laboratory research purposes. It is not suitable for human or animal consumption, nor for medical, veterinary, or household applications. Researchers should adhere to appropriate safety protocols and institutional guidelines.

Top 10 Frequently Asked Questions

1. What is Cagrilintide?
Cagrilintide is a research-grade long-acting acylated amylin analogue that acts as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). 

2. What is the mechanism of action of Cagrilintide?
It mimics the naturally occurring hormone amylin, inducing satiety, regulating gastric motility, glucagon secretion, and energy metabolism through central pathways. 

3. What are the potency characteristics of Cagrilintide?
Cagrilintide binds to AMYR1, AMYR2, AMYR3, and CTR, with a binding mode similar to amylin peptides but distinct conformational dynamics at calcitonin-family receptors. 

4. What clinical trial evidence supports Cagrilintide?
Phase 3 REDEFINE 1 trial demonstrated 11.8% mean weight loss with cagrilintide 2.4 mg vs 2.3% with placebo. In combination with semaglutide (CagriSema), 13.7% weight loss was observed in adults with type 2 diabetes. 

5. What are the most common side effects observed in clinical trials?
Gastrointestinal adverse events including nausea, vomiting, diarrhoea, and constipation were most common, predominantly mild-to-moderate in severity. 

6. What is the molecular identity of Cagrilintide?
Molecular formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂. Molecular weight: 4409.01 g/mol. CAS number: 1415456-99-3. 

7. What research applications is this product suitable for?
Amylin receptor pathway research, obesity and metabolic studies, gastric motility research, glucagon regulation, diabetic kidney research, and combination therapy models. 

8. How should this product be stored?
Lyophilized powder should be stored at -20°C, sealed, away from moisture and light. After reconstitution, store at -80°C and avoid repeated freeze-thaw cycles. 

9. Is Cagrilintide related to GLP-1 receptor agonists?
No. Cagrilintide is an amylin analogue that works through a distinct mechanism compared to GLP-1-based treatments. The combination of amylin and GLP-1 agonism has shown additive effects. 

10. Is Hubio Cagrilintide suitable for human use?
No. This product is intended solely for laboratory research purposes and is not suitable for human or animal consumption.

---

Ready to take the next step?
Secure your supply of Hubio Cagrilintide 10mg from a trusted source. Visit anabolicsteroidsonline.shop today to explore our selection of premium research products.